New antibody tested in healthy volunteers – no cure yet
NCT ID NCT07466940
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single dose of the experimental antibody SM17 in 30 healthy Chinese adults to see if it is safe and how the body processes it. The study did not aim to treat any disease. Results will help plan future trials for conditions like eczema, asthma, and inflammatory bowel disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PKUCare Luzhong Hospital
Zibo, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers